Lyra Therapeutics (LYRA) Short Interest Ratio & Short Volume → Obama’s Forever Term [exposed] (From Porter & Company) (Ad) Free LYRA Stock Alerts $0.33 +0.01 (+3.09%) (As of 05/28/2024 ET) Add Compare Share Share Short InterestStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Lyra Therapeutics Short Interest DataCurrent Short Interest603,000 sharesPrevious Short Interest413,800 sharesChange Vs. Previous Month+45.72%Dollar Volume Sold Short$214,547.40Short Interest Ratio0.2 Days to CoverLast Record DateMay 15, 2024Outstanding Shares60,970,000 sharesPercentage of Shares Shorted0.99%Today's Trading Volume1,620,275 sharesAverage Trading Volume9,110,327 sharesToday's Volume Vs. Average18% Short Selling Lyra Therapeutics ? Sign up to receive the latest short interest report for Lyra Therapeutics and its competitors with MarketBeat's FREE newsletter. Email Address Skip Charts & View Short Interest HistoryShort Interest ChartDays to Cover ChartShort Percent of Float ChartLYRA Short Interest Over TimeLYRA Days to Cover Over TimeLYRA Percentage of Float Shorted Over Time Ad Porter & CompanyObama’s Forever Term [exposed]Over a decade ago, I tried to warn you... Because the same forces are once again brewing… and what’s coming next will forever reshape everything you think you know about America. Start streaming it now at no cost here Lyra Therapeutics Short Interest History Export to ExcelReport DateTotal Shares Sold ShortDollar Volume Sold ShortChange from Previous ReportPercentage of Float ShortedDays to CoverPrice on Report Date 5/15/2024603,000 shares $214,547.40 +45.7%N/A0.2 $0.36 4/30/2024413,800 shares $2.14 million +24.0%N/A0.2 $5.16 4/15/2024333,600 shares $1.76 million +49.6%N/A1 $5.27 3/31/2024223,000 shares $1.39 million +8.1%N/A0.7 $6.22 3/15/2024206,300 shares $1.22 million +28.8%N/A0.8 $5.93 2/29/2024160,200 shares $842,652.00 -13.6%N/A0.6 $5.26 Get the Latest News and Ratings for LYRA and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Lyra Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 2/15/2024185,400 shares $927,000.00 +43.5%N/A0.8 $5.00 1/31/2024129,200 shares $587,860.00 -5.6%N/A0.6 $4.55 1/15/2024136,900 shares $736,522.00 -22.6%N/A0.6 $5.38 12/31/2023176,800 shares $926,432.00 +2.4%N/A0.9 $5.24 12/15/2023172,600 shares $802,590.00 -24.4%N/A0.7 $4.65 11/30/2023228,300 shares $755,673.00 -13.9%N/A0.6 $3.31 11/15/2023265,200 shares $766,428.00 -17.3%N/A0.7 $2.89 10/31/2023320,600 shares $952,182.00 +43.2%N/A0.9 $2.97 10/15/2023223,900 shares $801,562.00 -38.2%N/A0.6 $3.58 9/30/2023362,100 shares $1.42 million -14.0%N/A0.9 $3.91 9/15/2023421,100 shares $1.83 million +661.5%N/A1.2 $4.35 8/31/202355,300 shares $192,444.00 -19.5%N/A0.3 $3.48 8/15/202368,700 shares $245,946.00 -67.0%N/A0.4 $3.58 7/31/2023208,100 shares $670,082.00 -62.3%N/A1.1 $3.22 7/15/2023552,200 shares $1.69 million -0.1%N/A3.4 $3.06 6/30/2023552,600 shares $2.27 million +23.4%N/A4.2 $4.11 6/15/2023447,700 shares $1.34 million +56.8%N/A3.9 $2.99 5/31/2023285,500 shares $733,735.00 +1,513.0%N/A3.7 $2.57 5/15/202317,700 shares $46,197.00 -31.4%N/A0.5 $2.61 4/30/202325,800 shares $61,920.00 +27.1%N/A0.7 $2.40 4/15/202320,300 shares $48,517.00 +178.1%N/A0.6 $2.39 3/31/20237,300 shares $14,673.00 -29.1%N/A0.2 $2.01 3/15/202310,300 shares $21,012.00 -32.2%N/A0.3 $2.04 2/28/202315,200 shares $36,176.00 +22.6%N/A0.5 $2.38 2/15/202312,400 shares $30,256.00 +21.6%N/A0.4 $2.44 1/31/202310,200 shares $29,070.00 -21.5%N/A0.3 $2.85 1/15/202313,000 shares $36,010.00 -29.7%N/A0.2 $2.77 12/30/202218,500 shares $58,090.00 +44.5%N/A0.3 $3.14 12/15/202212,800 shares $34,944.00 -41.6%N/A0.2 $2.73 11/30/202221,900 shares $76,869.00 +0.5%N/A0.3 $3.51 11/15/202221,800 shares $85,020.00 No ChangeN/A0.3 $3.90 10/31/202221,800 shares $102,242.00 -27.6%N/A0.3 $4.69 10/15/202230,100 shares $144,480.00 -16.4%N/A0.9 $4.80 9/30/202236,000 shares $180,360.00 -45.4%N/A1 $5.01You won't believe what Citigroup just did to it's depositors (Ad)The FEDNOW Biden Dollar ends cash in a matter of WEEKS Stumbling Biden's dollar next phases begins Oct 21st This guide shows you what to do next. In a cashless society, Biden forces you to use the government's new "digital dollar"...CLICK HERE TO GET YOUR GUIDE NOW 9/15/202265,900 shares $392,764.00 -25.5%N/A1.6 $5.96 8/31/202288,400 shares $511,836.00 -18.8%N/A1.4 $5.79 8/15/2022108,800 shares $683,264.00 -22.6%N/A1.6 $6.28 7/31/2022140,600 shares $912,494.00 -44.2%N/A1.9 $6.49 7/15/2022252,000 shares $1.43 million -17.5%N/A2.7 $5.69 6/30/2022305,300 shares $1.72 million +13.6%N/A1.2 $5.65 6/15/2022268,700 shares $1.35 million -38.5%N/A1 $5.02 5/31/2022437,000 shares $2.34 million +5.1%N/A1.9 $5.35 5/15/2022415,800 shares $2.03 million +10.7%N/A1.8 $4.88 4/30/2022375,600 shares $2.12 million +50.0%N/A1.7 $5.65 4/15/2022250,400 shares $1.88 million +224.4%3.9%1.2 $7.51 3/31/202277,200 shares $310,344.00 +19.0%0.9%0.5 $4.02 3/15/202264,900 shares $262,845.00 -44.8%0.7%1.5 $4.05 2/28/2022117,500 shares $572,225.00 +36.3%1.2%2.4 $4.87 2/15/202286,200 shares $387,900.00 +9.1%0.9%1.6 $4.50 1/31/202279,000 shares $323,110.00 +5.6%0.8%1.3 $4.09 1/15/202274,800 shares $295,460.00 +4.0%0.8%1.2 $3.95 12/31/202171,900 shares $313,484.00 -5.8%0.8%1.2 $4.36 12/15/202176,300 shares $334,194.00 -1.0%0.8%1.4 $4.38 11/30/202177,100 shares $431,760.00 +2.5%0.8%1.4 $5.60 11/15/202175,200 shares $539,936.00 -51.4%0.9%1.5 $7.18 10/29/2021154,600 shares $1.13 million -3.6%1.8%3.3 $7.30 10/15/2021160,400 shares $1.26 million -20.9%1.9%3.4 $7.85 9/30/2021202,700 shares $1.85 million -0.3%2.3%4.2 $9.12 9/15/2021203,300 shares $1.68 million -3.1%2.4%2.9 $8.28 8/31/2021209,700 shares $1.50 million -11.0%2.4%2.5 $7.14 8/13/2021235,700 shares $1.64 million +1.3%2.7%2.1 $6.94 7/30/2021232,700 shares $1.50 million -2.8%2.7%1.9 $6.44 7/15/2021239,400 shares $1.78 million +0.3%2.8%1.9 $7.45 6/30/2021238,700 shares $1.92 million -43.6%2.8%1.8 $8.03 6/15/2021423,100 shares $3.88 million +17.9%4.9%3.6 $9.17 5/28/2021358,900 shares $2.58 million -13.2%4.1%3.4 $7.18 5/14/2021413,600 shares $3.09 million +14.1%4.8%4.6 $7.46 4/30/2021362,500 shares $3.69 million +10.9%4.4%2.4 $10.18 4/15/2021327,000 shares $3.56 million +4.1%3.9%2.1 $10.89 3/31/2021314,200 shares $3.51 million +11.3%3.8%2.1 $11.17 3/15/2021282,300 shares $3.95 million +15.4%3.4%1.8 $13.98 2/26/2021244,600 shares $3.42 million +73.6%3.1%1.3 $14.00 2/12/2021140,900 shares $1.86 million -1.4%1.8%0.7 $13.19 1/29/2021142,900 shares $1.53 million +9.3%1.8%1.1 $10.68 1/15/2021130,800 shares $1.43 million No Change1.6%1.1 $10.96 LYRA Short Interest - Frequently Asked Questions What is Lyra Therapeutics' current short interest? Short interest is the volume of Lyra Therapeutics shares that have been sold short but have not yet been covered or closed out. As of May 15th, investors have sold 603,000 shares of LYRA short. Learn More on Lyra Therapeutics' current short interest. Is Lyra Therapeutics' short interest increasing or decreasing? Lyra Therapeutics saw a increase in short interest during the month of May. As of May 15th, there was short interest totaling 603,000 shares, an increase of 45.7% from the previous total of 413,800 shares. Changes in short volume can be used to identify positive and negative investor sentiment. Investors that short sell a stock are betting that its price will decline in the future. An increase in short sale volume suggests bearish (negative) sentiment among investors. A decrease on short sale volume suggests bullish (positive) sentiment. How does Lyra Therapeutics' short interest compare to its competitors? Here is how the short interest of companies in the sector of "medical" compare to Lyra Therapeutics: PolyPid Ltd. (0.53%), Nephros, Inc. (0.03%), Meihua International Medical Technologies Co., Ltd. (0.12%), PAVmed Inc. (5.35%), Inspira Technologies Oxy B.H.N. Ltd. (0.86%), Femasys Inc. (4.06%), NeuroOne Medical Technologies Co. (1.11%), Microbot Medical Inc. (2.12%), NEXGEL, Inc. (0.44%), STRATA Skin Sciences, Inc. (0.42%), Which stocks are the most shorted right now? As of the most recent reporting period, the following stocks had the largest short interest positions: T-Mobile US, Inc. ($3.81 billion), Charter Communications, Inc. ($3.30 billion), Occidental Petroleum Co. ($3.10 billion), General Motors ($2.84 billion), Moderna, Inc. ($2.77 billion), AppLovin Co. ($2.22 billion), Royal Caribbean Cruises Ltd. ($2.22 billion), Coinbase Global, Inc. ($2.16 billion), Tractor Supply ($2.12 billion), and Williams-Sonoma, Inc. ($2.12 billion). View all of the most shorted stocks. What does it mean to sell short Lyra Therapeutics stock? Short selling LYRA is an investing strategy that aims to generate trading profit from Lyra Therapeutics as its price is falling. LYRA shares are trading up $0.01 today. To short a stock, an investor borrows shares, sells them and buys the shares back on the public market later to return it to the lender. Short sellers are betting that a stock will decline in price. If the stock does drop after selling, the short seller buys it back at a lower price and returns it to the lender. The difference between the sell price and the buy price is the trader's profit. How does a short squeeze work against Lyra Therapeutics? A short squeeze for Lyra Therapeutics occurs when it has a large amount of short interest and its stock appreciates in price. This forces short sellers to cover their short interest positions by buying actual shares of LYRA, which in turn drives the price of the stock up even further. How often is Lyra Therapeutics' short interest reported? Short interest is typically published by a stock exchange once per month. However, NASDAQ publishes a report for U.S. stocks, including LYRA, twice per month. The most recent reporting period available is May, 15 2024. More Short Interest Resources from MarketBeat Related Companies: Allurion Technologies Short Interest Data Pro-Dex Short Interest Data enVVeno Medical Short Interest Data Neuronetics Short Interest Data Monogram Orthopaedics Short Interest Data Apyx Medical Short Interest Data Carmell Short Interest Data DarioHealth Short Interest Data SEP Acquisition Short Interest Data Cytosorbents Short Interest Data Short Interest Tools: Stocks to Short Largest Short Interest Positions Short Interest Increases Short Interest Decreases Short Interest Reporting Dates This page (NASDAQ:LYRA) was last updated on 5/29/2024 by MarketBeat.com Staff From Our PartnersThe #1 Crypto That You Don’t Own… YetCrypto 101 Media4 Cryptos BETTER than BitcoinTrue Market InsidersA once-in-a-century investment opportunityStansberry ResearchWrite this ticker symbol down…StocksToTradeHe Is Giving Away BitcoinCrypto Swap ProfitsMust-See: Elon’s New Invention is Absolutely InsaneInvestorPlaceNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemWeiss RatingsTop 5 AI Stocks to Buy for 2024Market Moving Trends Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Lyra Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.